NGR-TNF in Treating Patients With Advanced Solid Tumors

You may be eligible if

• DISEASE CHARACTERISTICS:
• Diagnosis of advanced solid tumor not amenable to any clinical improvement by current standard treatments
• * Preferably tumors well known to be very angiogenic (e.g., renal, colon, thyroid, and head and neck cancers)
• No clinical signs of CNS involvement
• PATIENT CHARACTERISTICS:
• Age
• Over 18
• Performance status
• ECOG 0-2 OR
• WHO 0-2
• Life expectancy
• Not specified
• Hematopoietic
• Absolute neutrophil count \> 1,500/mm\^3
• Platelet count \> 100,000/mm\^3
• Hepatic
• Bilirubin \< 1.5 times upper limit of normal (ULN)
• AST and/or ALT \< 2.5 times ULN (5 times ULN in the presence of liver metastases)
• Renal
• Creatinine \< 1.5 times ULN
• Cardiovascular
• Cardiac function normal
• No uncontrolled hypertension
• No condition in which hypovolemia and its consequences (e.g., increased stroke volume, elevated blood pressure) or hemodilution could represent a risk to the patient
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 3 months after study participation
• No active or uncontrolled systemic infection
• No other uncontrolled disease, serious illness, or medical condition that would preclude study participation
• No known hypersensitivity/allergic reaction to human albumin preparations or any of the excipients
• No psychological, familial, sociological, or geographical condition that would preclude study compliance
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• At least 28 days since prior immunotherapy
• Chemotherapy
• At least 28 days since prior chemotherapy and recovered
• Endocrine therapy
• At least 28 days since prior hormonal therapy
• Radiotherapy
• At least 28 days since prior radiotherapy and recovered
• No prior radiotherapy to \> 25% of bone marrow reserve
• Surgery
• More than 2 weeks since prior surgery
• Other
• No other concurrent anticancer therapy
• No other concurrent investigational agents